Skip to main content
. Author manuscript; available in PMC: 2007 Sep 1.
Published in final edited form as: Clin Exp Pharmacol Physiol. 2007 Sep;34(9):906–911. doi: 10.1111/j.1440-1681.2007.04638.x

Table 1.

Pathological conditions associated with arginase-mediated impairment in NO synthesis.

Pathological condition References
Hypertension 30,30,32,47,48
Aging 27,49
Ischemia-reperfusion 50
Diabetes 51,56,57
Erectile dysfunction 56
Asthma 59
Cystic fibrosis 60
Glumerulonephritis 61
Psoriasis 62
Arthritis 63
Sickle cell disease 64
Vascular remodeling 72,73